Level Bio AB (publ)

NGM:LEVBIO Stock Report

Market Cap: SEK 16.4m

Level Bio Management

Management criteria checks 2/4

We currently do not have sufficient information about the CEO.

Key information

Joakim Granemo

Chief executive officer

n/a

Total compensation

CEO salary percentagen/a
CEO tenure3.1yrs
CEO ownershipn/a
Management average tenureno data
Board average tenure5.3yrs

Recent management updates

Recent updates

Analysis Article • Jun 02

Do AlphaHelix Molecular Diagnostics's (NGM:ALPH) Earnings Warrant Your Attention?

It's only natural that many investors, especially those who are new to the game, prefer to buy shares in 'sexy' stocks...
Analysis Article • Feb 10

Should You Be Adding AlphaHelix Molecular Diagnostics (NGM:ALPH) To Your Watchlist Today?

For beginners, it can seem like a good idea (and an exciting prospect) to buy a company that tells a good story to...
Analysis Article • Nov 03

I Ran A Stock Scan For Earnings Growth And AlphaHelix Molecular Diagnostics (NGM:ALPH) Passed With Ease

Some have more dollars than sense, they say, so even companies that have no revenue, no profit, and a record of falling...
Analysis Article • Aug 18

AlphaHelix Molecular Diagnostics AB (publ) (NGM:ALPH) Stock Rockets 35% As Investors Are Less Pessimistic Than Expected

Despite an already strong run, AlphaHelix Molecular Diagnostics AB (publ) ( NGM:ALPH ) shares have been powering on...
Analysis Article • Mar 07

Do Its Financials Have Any Role To Play In Driving AlphaHelix Molecular Diagnostics AB (publ)'s (NGM:ALPH) Stock Up Recently?

Most readers would already be aware that AlphaHelix Molecular Diagnostics' (NGM:ALPH) stock increased significantly by...
Analysis Article • Nov 22

Declining Stock and Decent Financials: Is The Market Wrong About AlphaHelix Molecular Diagnostics AB (publ) (NGM:ALPH)?

It is hard to get excited after looking at AlphaHelix Molecular Diagnostics' (NGM:ALPH) recent performance, when its...

CEO Compensation Analysis

How has Joakim Granemo's remuneration changed compared to Level Bio's earnings?
DateTotal CompensationSalaryCompany Earnings
Jun 30 2026n/an/a

SEK 5m

Mar 31 2026n/an/a

-SEK 3m

Dec 31 2025n/an/a

-SEK 4m

Sep 30 2025n/an/a

-SEK 4m

Jun 30 2025n/an/a

-SEK 5m

Mar 31 2025n/an/a

-SEK 6m

Dec 31 2024n/an/a

-SEK 8m

Sep 30 2024n/an/a

-SEK 11m

Jun 30 2024n/an/a

-SEK 12m

Mar 31 2024n/an/a

-SEK 11m

Dec 31 2023SEK 1mSEK 981k

-SEK 9m

Sep 30 2023n/an/a

-SEK 5m

Jun 30 2023n/an/a

-SEK 4m

Mar 31 2023n/an/a

-SEK 4m

Dec 31 2022SEK 866kSEK 768k

-SEK 2m

Compensation vs Market: Insufficient data to establish whether Joakim's total compensation is reasonable compared to companies of similar size in the Swedish market.

Compensation vs Earnings: Joakim's compensation has been consistent with company performance over the past year.

CEO

Joakim Granemo (40 yo)

3.1yrs
Tenure

Mr. Joakim Granemo is Chief Executive Officer of Level Bio AB (publ) from August 2023 and its Director from October 2022.

Board Members

NamePositionTenureCompensationOwnership
Joakim Granemo
CEO & Director3.9yrsno datano data
Ulrica Karlsson
CFO & Directorno dataSEK 945.00kno data
Helene Olsson
Director of Cybergene ABno dataSEK 605.00kno data
Mikael Kubista
Director2.7yrsSEK 25.00kno data
Mikael Havsjo
Director15.5yrsSEK 50.00kno data
Artur Aira
Chairman8.7yrsSEK 100.00kno data
Tobias Schön
Director3.7yrsSEK 50.00k6.85%
SEK 1.1m
Neven Zoric
Director6.7yrsSEK 50.00kno data
Claes Gustafsson
Director of Techtum Lab ABno dataSEK 976.00kno data
5.3yrs
Average Tenure
57yo
Average Age

Experienced Board: LEVBIO's board of directors are considered experienced (5.3 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/09/18 05:48
End of Day Share Price 2026/09/18 00:00
Earnings2026/06/30
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Level Bio AB (publ) is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.